Verrica Pharmaceuticals (VRCA) Competitors $6.61 -0.39 (-5.57%) Closing price 04:00 PM EasternExtended Trading$6.78 +0.18 (+2.65%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VRCA vs. ALDX, VOR, CRVS, SGMT, DBVT, ANNX, AVTE, ALLO, TVRD, and ZYBTShould you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Aldeyra Therapeutics (ALDX), Vor Biopharma (VOR), Corvus Pharmaceuticals (CRVS), Sagimet Biosciences (SGMT), DBV Technologies (DBVT), Annexon (ANNX), Aerovate Therapeutics (AVTE), Allogene Therapeutics (ALLO), Tvardi Therapeutics (TVRD), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry. Verrica Pharmaceuticals vs. Its Competitors Aldeyra Therapeutics Vor Biopharma Corvus Pharmaceuticals Sagimet Biosciences DBV Technologies Annexon Aerovate Therapeutics Allogene Therapeutics Tvardi Therapeutics Zhengye Biotechnology Verrica Pharmaceuticals (NASDAQ:VRCA) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Do insiders and institutionals have more ownership in VRCA or ALDX? 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 9.6% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer VRCA or ALDX? In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 2 mentions for Verrica Pharmaceuticals and 1 mentions for Aldeyra Therapeutics. Verrica Pharmaceuticals' average media sentiment score of 1.87 beat Aldeyra Therapeutics' score of 1.26 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Verrica Pharmaceuticals Very Positive Aldeyra Therapeutics Positive Which has more risk & volatility, VRCA or ALDX? Verrica Pharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Do analysts prefer VRCA or ALDX? Verrica Pharmaceuticals currently has a consensus target price of $8.00, suggesting a potential upside of 21.03%. Aldeyra Therapeutics has a consensus target price of $9.50, suggesting a potential upside of 83.75%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Verrica Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Aldeyra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is VRCA or ALDX more profitable? Verrica Pharmaceuticals' return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Verrica PharmaceuticalsN/A N/A -145.63% Aldeyra Therapeutics N/A -72.58%-52.32% Which has better earnings & valuation, VRCA or ALDX? Aldeyra Therapeutics has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerrica Pharmaceuticals$7.57M80.76-$76.58M-$1.20-5.51Aldeyra TherapeuticsN/AN/A-$55.85M-$0.97-5.33 SummaryAldeyra Therapeutics beats Verrica Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRCA vs. The Competition Export to ExcelMetricVerrica PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.74M$2.50B$5.70B$9.51BDividend YieldN/A1.75%4.69%4.01%P/E Ratio-5.519.0528.0720.06Price / Sales80.76757.79449.2099.44Price / CashN/A165.2136.2258.56Price / Book-60.095.168.665.87Net Income-$76.58M$30.99M$3.25B$258.55M7 Day Performance709.75%7.74%4.20%2.23%1 Month Performance1,001.67%16.18%10.82%12.76%1 Year Performance-8.83%-1.03%34.70%19.36% Verrica Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRCAVerrica Pharmaceuticals4.1333 of 5 stars$6.61-5.6%$8.00+21.0%-90.2%$64.74M$7.57M-5.5140Positive NewsGap DownALDXAldeyra Therapeutics2.7521 of 5 stars$5.01+7.7%$9.50+89.6%+39.1%$300.08MN/A-5.1610Positive NewsUpcoming EarningsVORVor Biopharma3.8804 of 5 stars$2.39-4.4%$5.63+135.5%+129.7%$298.65MN/A-1.45140High Trading VolumeCRVSCorvus Pharmaceuticals2.6722 of 5 stars$4.35+5.1%$15.00+244.8%+118.9%$296.54MN/A-4.4430Positive NewsSGMTSagimet Biosciences2.6714 of 5 stars$9.46-0.1%$26.60+181.2%+222.8%$290.14M$2M-5.388News CoverageAnalyst ForecastInsider TradeDBVTDBV Technologies3.9009 of 5 stars$10.58-2.1%$14.75+39.5%+102.4%$289.68M$4.15M-2.1580Upcoming EarningsGap UpANNXAnnexon2.4431 of 5 stars$2.61+1.2%$12.50+378.9%-58.1%$286.34MN/A-2.2160AVTEAerovate TherapeuticsN/A$9.82-6.7%N/A-86.8%$284.63MN/A-3.2820High Trading VolumeALLOAllogene Therapeutics3.2575 of 5 stars$1.29+0.8%$8.44+554.6%-48.1%$282.16M$20K-1.05310Positive NewsTVRDTvardi TherapeuticsN/A$29.83+9.1%$64.25+115.4%N/A$279.21M$7.14M0.0080Gap UpHigh Trading VolumeZYBTZhengye BiotechnologyN/A$5.87-0.3%N/AN/A$276.86M$186.36M0.00278Positive News Related Companies and Tools Related Companies ALDX Alternatives VOR Alternatives CRVS Alternatives SGMT Alternatives DBVT Alternatives ANNX Alternatives AVTE Alternatives ALLO Alternatives TVRD Alternatives ZYBT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRCA) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRCA Stock Alerts